Non-APOE4 carriers do not benefit from treatment with lecanemab. Lecanemab reduces the rate of progression of APOE4 carriers closer to that of non-carriers in mild Alzheimer's disease. While rare ...

Anti-amyloid drugs only modestly slow down the progression of Alzheimer's disease in APOE4 carriers and have no effect on non-carriers. APOE4 carriers have more amyloid in their brain so removing ...

In addition to AD, APOE4 carriers are at an increased risk of cardiovascular diseases (CVD) and cognitive impairment, as well as a reduced risk of many types of cancer. APOE4 carriers are at an ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced promising results from its recent Phase II/III clinical trial for its lead drug candidate, Buntanetap, targeting Alzheimer’s disease (AD).

Figure 3: In APOE4 carriers, cholesterol (green) accumulates around the oligodendrocyte nucleus ... More (blue). In contrast, cholesterol in APOE3/3 individuals is highly dispersed throughout the ...

A new genetic variant in individuals who are APOE4 carriers is linked to a 70% reduction in the risk for Alzheimer's disease (AD), new research suggested. The variant occurs on the fibronectin 1 ...

Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in apolipoprotein ε4 allele (APOE4) carriers with early Alzheimer disease (AD). Valiltramiprosate is an ...

Because APOE4 testing is not typically recommended as part of preventive care, carriers mostly don’t know they have this variant, even if they are trying to do proactive things like diet and ...

1–8 ALZ-801 Phase 2 Biomarker Trial Biomarker Effects of ALZ-801 in APOE4 Carriers with Early Alzheimer's Disease (NCT04693520): This trial was designed to evaluate the effects of 265 mg twice ...

Among APOE4 carriers, women had significantly faster tau deposits in the inferior-temporal region. Sex differences in tau may help explain why women face higher Alzheimer's dementia risk than men.

Comparing the bottom and top percentiles of exposure of all nine metals, the mean difference of DSC scores was -0.30 for APOE4 carriers and -0.10 for noncarriers. Identifying modifiable risk ...